Title |
Concomitant disseminated histoplasmosis and disseminated tuberculosis after tumor necrosis factor inhibitor treatment: a case report
|
---|---|
Published in |
BMC Infectious Diseases, January 2017
|
DOI | 10.1186/s12879-016-2097-7 |
Pubmed ID | |
Authors |
Juan E. Muñoz-Oca, Martha L. Villarreal Morales, Aracelis Nieves-Rodriguez, Lemuel Martínez-Bonilla |
Abstract |
Tumor necrosis factor antagonist inhibitors have transformed the approach to patients with severe autoimmune conditions, such as rheumatoid arthritis. Although the therapy can be highly effective, TNF-α inhibitors are associated with an increased risk of opportunistic infections. Here, we report a case of concomitant disseminated histoplasmosis and tuberculosis in a 65-year-old female with rheumatoid arthritis treated with TNF-α inhibitor. Both conditions can be found in disseminated form in immunosuppressed hosts, but co-infection is rare with only a few cases having been reported, to our knowledge, all in HIV patients. This case posed a considerable challenge for diagnosis and treatment due to the unusual disseminated co-infection, the overlapping symptoms, and the interactions between medications. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 50 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 9 | 18% |
Researcher | 5 | 10% |
Student > Doctoral Student | 5 | 10% |
Student > Bachelor | 5 | 10% |
Other | 4 | 8% |
Other | 13 | 26% |
Unknown | 9 | 18% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 26 | 52% |
Nursing and Health Professions | 5 | 10% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 6% |
Immunology and Microbiology | 2 | 4% |
Biochemistry, Genetics and Molecular Biology | 1 | 2% |
Other | 3 | 6% |
Unknown | 10 | 20% |